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Anderson-Fabry disease (AFD) is a rare, X-linked, lysosomal storage disease caused by deficient 
activity of the lysosomal enzyme α-galactozidase A, with accumulation of globotriaosylceramide 
and related glycosphingolipids in different organs and tissues. The disease manifests primarily in 
affected males, with severe pain from the childhood, kidney failure, heart disease and strokes 
occurring during the 4th and 5th decade of life, or even earlier. Heterozygous females may also 
develop serious clinical manifestations (1).  
In recent years, enzyme replacement therapy (ERT) has become standard treatment of patients 
with AFD. Two enzyme preparations are currently available for ERT: agalsidase alfa (Replagal, 
TKT Europe), and agalsidase beta (Fabrazyme, Genzyme) (2). Both preparations were approved 
on an expedited basis because of beneficial effect on target organs with reduction of lysosomal 
inclusions. It was shown that agalsidase beta after 24 weeks of treatment slows the decline of 
glomerular filtration in patients with AFD (3). Study performed with agalsidase alfa failed to 
demonstrate significant change in inulin clearance from baseline after 20 weeks of double-blind 
treatment or after 6 months of open-label treatment. However, authors showed that ERT cleared 
globotriaosylceramide deposits from the target organs (4). Both studies were underpowered and 
suffered from serious disadvantages. The main problem of both studies was limited number of 
patients. While standard medical treatment used for treatment of proteinuria or prevention of 
stroke and cardiac disease is likely to be beneficial in patients with AFD, more patients are 
needed for demonstration of ERT efficacy. Additional problem is production of neutralizing 
antibodies which decrease enzyme activity. The effect of anti-agalsidase antibodies on the 
likelihood of therapeutic success should be evaluated. However, the main problem remains the 
extremely expensive therapy with annual cost per patient exceeding € 150.000. Considering ERT 
as „moderately effective“ life-long therapy, we believe that more evidence is needed to 
demonstrate its cost-effectiveness. 
We have recently described two patients who received the renal allograft from a female deceased 
donor who died from the heart attack and had empty medical anamnesis. Deterioration of graft 
function with persistent proteinuria of 2 g/l demanded graft biopsy. Pathohistological finding was 
suggestive of Anderson-Fabry disease. This graft was lost because of the bleeding after drainage 
of the lymphocele which demanded graftectomy. Kidney biopsy performed three months later (9 
 4 
months after transplantation) in other recipient who received organ from the same donor 
demonstrated significant clearance of globotriaosylceramide deposits from the kidney (5). 
Protocol biopsy performed one year later (21 month after transplantation) showed almost 
complete clearance of globotriaosylceramide deposits from the graft. More importantly, 
proteinuria decreased from 1.66 g/l at 3 months after transplantation, to 0.98 g/l at 12 months, 
and 0.17 g/l at 20 months after transplantation. Glomerular filtration rate was stable at 75-85 
ml/min as determined by the Cockroft-Gault formula. Enzyme activity measured in leukocytes at 
20 months after transplantation was 98 (normal laboratory value 89 nmol/h/mg of protein). The 
patient was not treated with ACE inhibitor because of the rise in serum creatinine concentration.  
Our experience demonstrates that proper enzyme activity may not only clear 
globotriaosylceramide deposits from the kidney but may decrease proteinuria and maintain 
glomerular filtration rate even without the additive effect of ACEi. This is very important while 
shows that higher than currently recommended doses are needed to achieve therapeutic targets 
(Fabrazyme 1.0 mg/kg, and Replagal 0.2 mg/kg every other week). It has recently become 
evident that more intensive treatment may improve outcome in patients with AFD (6,7). Our case 
demonstrates that structural and functional changes in target organs may be almost completely 
reversible in the setting of normal enzyme activity and raises the possibility that the same results 
may be achieved with increase dosage of ERT in patients with AFD. Enzyme replacement 
therapy in AFD nephropathy should probably been instituted earlier and in higher doses, together 
with the standard concomitant medications (ACE inhibitors or angiotensin receptors blockers).  
Higher doses of ERT could probably solve the problem of neutralizing antibodies as was 
observed in patients with haemophilia (8). Individualized dosing of ERT seems promising (6), 
but needs an appropriate surrogate marker for assessment of treatment efficacy. 
Larger trials are urgently needed to find an optimal dosing regimen, and possibly, to identify 
more efficient enzyme formulation. Modest effect of expensive, but perhaps inadequate dose of 
ERT should probably be changed to the full dose treatment that will be cost-effective and 
associated with improved outcome.  
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